A neuropsychological perspective on defining cognitive impairment in the clinical study of Alzheimer’s disease: Towards a more continuous approach

Manuscript Number: 

21-5098R1

Author(s): 
Jessica Alber, David Faust, Serge Gauthier, Michael Gold, John Harrison, Roos J. Jutten, Athene K.W. Lee, Paul Maruff, José-Luis Molinuevo, Sietske A.M. Sikkes, Peter J. Snyder, Louisa Thompson, Henrik Zetterberg

Disclosures

Jessica Alber

  • Nothing to Disclose

David Faust

  • Nothing to Disclose

Serge Gauthier

  • Nothing to Disclose

Michael Gold

  • Nothing to Disclose

John Harrison

  • Consulting Fees:
    Dr. Harrison reports receipt of personal fees in the past 2 years from Actinogen, AlzeCure, Aptinyx, Astra Zeneca, Athira Therapeutics, Axoltis, Axon Neuroscience, Axovant, Bial Biotech, Biogen Idec, BlackThornRx, Boehringer Ingelheim, Brands2life, Cerecin, Cognito, Cognition Therapeutics, Compass Pathways, Corlieve, Curasen, EIP Pharma, Eisai, G4X Discovery, GfHEU, Heptares, ImPACT, Ki Elements, Lundbeck, Lysosome Therapeutics, MyCognition, Neurocentria, Neurocog, Neurodyn Inc, Neurotrack, the NHS, Novartis, Novo Nordisk, Nutricia, Probiodrug, Prothena, Recognify, Regeneron, reMYND, Rodin Therapeutics, Samumed, Sanofi, Signant, Syndesi Therapeutics, Takeda, Vivoryon Therapeutics and Winterlight Labs.
    Equity:
    Options in Neurotrack Inc.
    Patents/Royalties
    I am a joint holder of patents with My Cognition Ltd.

Roos J. Jutten

  • Nothing to Disclose

Athene K.W. Lee

  • Nothing to Disclose

Paul Maruff

  • Nothing to Disclose

José-Luis Molinuevo

  • Nothing to Disclose

Sietske A.M. Sikkes

  • Consulting Fees:
    Dr. Sikkes received consulting fees in the past two years from Biogen, Boehringer and Toyama. All funds were paid to her institution.

Peter J. Snyder

  • Nothing to Disclose

Louisa Thompson

  • Nothing to Disclose

Henrik Zetterberg

  • Nothing to Disclose